<?xml version="1.0" encoding="UTF-8"?>
<p id="Par100">Refractory angina is a debilitating condition representing an emerging burden for health systems [
 <xref ref-type="bibr" rid="CR2">2</xref>]. A recent Ontario-based study conservatively estimated the annualized cost of angina-related disability including direct, indirect and system costs at $19,209 per patient/year [
 <xref ref-type="bibr" rid="CR1">1</xref>]. In this scenario, the only pharmacological therapy that has been approved for RA in the last 40Â years is the late sodium current blocker ranolazine, whose effectiveness has, however, been recently questioned [
 <xref ref-type="bibr" rid="CR25">25</xref>].
</p>
